secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202389
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio reports rese-cel activity without preconditioning in 4 PV patients; ASGCT presentation May 14
--------------------------------------------------------------------------------

- 2 of 4 refractory PV patients on rese-cel at lowest dose showed compelling clinical activity through 6 months without preconditioning.
- Complete peripheral B-cell elimination observed in 3 of 4 patients; 3 of 4 remained off all immunomodulators and steroids as of April 2, 2026.
- Safety: 1 of 4 patients had Grade 1 CRS; no ICANS of any grade. Additional patients enrolled at higher dose in RESET-PV.
- RESET-SLE trial initial dose cohort (no preconditioning) fully enrolled; initial data expected first half 2026.
- Data to be presented at ASGCT 2026 Annual Meeting on May 14, 2026; higher dose durability data anticipated H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/0001193125-26-202389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/d110169d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer